Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dianhydrogalactitol - TuHURA Biosciences

Next Previous
Drug Profile

Dianhydrogalactitol - TuHURA Biosciences

Alternative Names: DAG for Injection; Dianhydrodulcitol; Diepoxydulcitol; Diepoxygalactitol; NSC-1323313; VAL-083

Latest Information Update: 06 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DelMar Pharmaceuticals
  • Developer DelMar Pharmaceuticals; Global Coalition for Adaptive Research; Guangxi Wuzhou Pharmaceutical; National Cancer Institute (USA); TuHURA Biosciences; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cytostatics; Epoxy compounds; Ethylene glycols; Small molecules
  • Mechanism of Action Alkylating agents; BRD4 protein inhibitors; Cell cycle inhibitors; DNA damage stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Ovarian cancer; Medulloblastoma; Diffuse intrinsic pontine glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia; Lung cancer
  • Suspended Diffuse intrinsic pontine glioma; Glioblastoma; Medulloblastoma; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 06 Oct 2025 CTP Push700263430: Updated KDM for trial completion info and relevant HE added
  • 30 Dec 2024 DelMar Pharmaceuticals completes phase II clinical trials in Glioblastoma (First-line therapy, Newly diagnosed) in China (IV) (NCT03050736)
  • 17 Oct 2024 Kintara Therapeutics has merged with TuHURA Biosciences to form TuHURA Biosciences

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top